LY-3023414

Generic Name: LY-3023414

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₆N_₄O_₃

CAS Number: 1386874-06-1

Unique Ingredient Identifier: C88817F47Y

Background: LY3023414 has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.

Clinical Trials

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Endometrial Cancer
Ovarian Cancer

Interventions: Drug: Letrozole
Drug: LY3023414
Drug: Abemaciclib
Drug: Zotatifin
Drug: Metformin

First Posted Date: 2018-09-18

Last Posted Date: 2024-11-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 130

Registration Number: NCT03675893

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Phase 2

Completed

Conditions: Ann Arbor Stage III Non-Hodgkin Lymphoma
Recurrent Glioma
Recurrent Hepatoblastoma
Recurrent Langerhans Cell Histiocytosis
Recurrent Malignant Solid Neoplasm
Recurrent Osteosarcoma
Stage III Osteosarcoma AJCC v7
Stage IV Soft Tissue Sarcoma AJCC v7
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Recurrent Malignant Germ Cell Tumor

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: FDG-Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Drug: Samotolisib
Procedure: X-Ray Imaging

First Posted Date: 2017-07-11

Last Posted Date: 2025-01-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT03213678

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States

and more 124 locations

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Juvenile Xanthogranuloma
Langerhans Cell Histiocytosis
Malignant Glioma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Ewing Sarcoma
Recurrent Osteosarcoma
Recurrent Primary Central Nervous System Neoplasm
Refractory Hepatoblastoma
Refractory Medulloblastoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Other: Laboratory Biomarker Analysis
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Mutation Carrier Screening
Procedure: Bone Scan
Drug: Larotrectinib Sulfate
Procedure: Computed Tomography
Drug: Olaparib
Drug: Palbociclib
Drug: Tazemetostat
Drug: Samotolisib
Drug: Selumetinib Sulfate
Drug: Ensartinib
Drug: Vemurafenib
Drug: Ulixertinib
Drug: Tipifarnib
Drug: Erdafitinib
Procedure: Magnetic Resonance Imaging
Other: Pharmacological Study
Drug: Selpercatinib
Procedure: Radionuclide Imaging
Procedure: Positron Emission Tomography
Procedure: X-Ray Imaging

First Posted Date: 2017-05-16

Last Posted Date: 2025-05-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1376

Registration Number: NCT03155620

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 169 locations

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

Phase 2

Completed

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Abemaciclib
Drug: Gemcitabine
Drug: LY3023414
Drug: Capecitabine

First Posted Date: 2016-12-05

Last Posted Date: 2019-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 106

Registration Number: NCT02981342

Locations: 🇺🇸
Illinois CancerCare, Peoria, Illinois, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States

and more 10 locations

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Soft Tissue Sarcoma
Colon Cancer
Solid Tumor
Breast Cancer
Cholangiocarcinoma

Interventions: Drug: LY3039478
Drug: LY3023414
Drug: Abemaciclib
Drug: Taladegib
Drug: Cisplatin
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2016-05-27

Last Posted Date: 2020-08-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 94

Registration Number: NCT02784795

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 8 locations

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Conditions: Cancer

First Posted Date: 2015-12-17

Last Posted Date: 2025-03-03

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT02632994

Locations: 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸
UCLA Medical Center, Torrance, California, United States
🇺🇸
Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer
Recurrent Endometrial Cancer

Interventions: Drug: LY3023414

First Posted Date: 2015-09-15

Last Posted Date: 2023-02-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT02549989

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 3 locations

A Study of LY3023414 in Japanese Participants With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasm

Interventions: Drug: LY3023414

First Posted Date: 2015-09-01

Last Posted Date: 2018-07-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT02536586

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Tokyo, Japan

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: LY3023414
Drug: Necitumumab

First Posted Date: 2015-05-13

Last Posted Date: 2020-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 31

Registration Number: NCT02443337

Locations: 🇺🇸
Southern Cancer Center, P.C., Mobile, Alabama, United States
🇺🇸
Comprehensive Cancer Care and Research Institute of Colorado, Englewood, Colorado, United States
🇺🇸
Chattanooga Oncology Hematology, Chattanooga, Tennessee, United States

and more 10 locations

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: LY3023414
Drug: Placebo
Drug: Enzalutamide

First Posted Date: 2015-04-02

Last Posted Date: 2021-05-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 142

Registration Number: NCT02407054

Locations: 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸
Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States

and more 33 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy